Company intelligence / Profile preview

Hi-Art

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Hi-Art is a biotechnology company specializing in the development of regenerative medicine therapies for cardiovascular diseases, with a primary focus on heart failure. The company utilizes a proprietary platform to produce high-purity, human-induced pluripotent stem cell (iPSC)-derived cardiomyocytes intended for myocardial repair. By combining advanced cell engineering with specialized delivery systems, Hi-Art aims to restore cardiac function in patients with severe heart damage. Their approach represents a significant shift from traditional symptom management to active tissue regeneration in the field of cardiology.

Therapeutic areas: Cardiovascular
Modalities: Cell therapyInduced pluripotent stem cell derived therapyDevice
Industry: Biotech

Partnerships

Tsinghua UniversityPeking University First Hospital

Beyond the preview

Go deeper on Hi-Art.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hi-Art.

Explore the full profile